Nurix TherapeuticsNRIX
About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Employees: 286
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
709% more call options, than puts
Call options by funds: $777K | Put options by funds: $96K
27% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 51
6% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 32
2% less funds holding
Funds holding: 175 [Q4 2024] → 171 (-4) [Q1 2025]
3.01% less ownership
Funds ownership: 114.49% [Q4 2024] → 111.48% (-3.01%) [Q1 2025]
34% less capital invested
Capital invested by funds: $1.53B [Q4 2024] → $1.01B (-$523M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Oppenheimer Matthew Biegler | 166%upside $30 | Outperform Reiterated | 31 Jul 2025 |
Morgan Stanley Terence Flynn | 42%upside $16 | Equal-Weight Maintained | 15 Jul 2025 |
HC Wainwright & Co. Robert Burns | 202%upside $34 | Buy Maintained | 14 Jul 2025 |
UBS David Dai | 131%upside $26 | Buy Maintained | 10 Jul 2025 |
Stephens & Co. Sudan Loganathan | 166%upside $30 | Overweight Reiterated | 10 Jul 2025 |
Financial journalist opinion
Based on 5 articles about NRIX published over the past 30 days









